57154-24-2

Upstream product

• 111-83-1 1-bromo-octane 
• 108-44-1 1-amino-3-methylbenzene 
• 18908-66-2 3-bromomethylheptane 

Downstream Products

• 1439365-37-3 2,2'-(2-((4-(dioctylamino)-2-methylphenyl)diazenyl)-5-((4-n itrophenyl)diazenyl)-1 ,4-phenylene )bis( oxy)diethanol 
• 1439365-38-4 2,2'-(2-((4-(dioctylamino)-2-methylphenyl)diazenyl)-5-((4-nitrophenyl)diazenyl)-1,4-phenylene)bis(oxy)bis(ethane-2,1-diyl) bis(3-chloropropanoate) 
• 1439365-39-5 2,2'-(2-((4-(dioctylamino)-2-methylphenyl)diazenyl)-5-((4-nitrophenyl)diazenyl)-1 ,4-phenylene )bis( oxy)bis( ethane-2, 1-diyl)diacrylate 
• 1439365-36-2 2,2'-(2-((4-(dioctylamino)-2-methylphenyl)diazenyl)-5-((4-nitrophenyl)diazenyl)-1 ,4-phenylene)bis(oxy)bis(ethane-2, 1-diyl)diacetate 

Relevant academic research and scientific papers

Pharmacodynamic Functions of Synthetic Derivatives for Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis

Drug resistant bacteria have emerged, so robust methods are needed to evaluate combined activities of known antibiotics as well as new synthetic compounds as novel antimicrobial agents to treatment efficacy in severe bacterial infections. Marine natural products (MNPs) have become new strong leads in the drug discovery endeavor and an effective alternative to control infections. Herein, we report the bioassay guided fractionation of marine extracts from the sponges Lendenfeldia, Ircinia, and Dysidea that led us to identify novel compounds with antimicrobial properties. Chemical synthesis of predicted compounds and their analogs has confirmed that the proposed structures may encode novel chemical structures with promising antimicrobial activity against the medically important pathogens. Several of the synthetic analogs exhibited potent and broad spectrum in vitro antibacterial activity, especially against the Methicillin-resistant Staphylococcus aureus (MRSA) (MICs to 12.5 μM), Mycobacterium tuberculosis (MICs to 0.02 μM), uropathogenic Escherichia coli (MIC o 6.2 μM), and Pseudomonas aeruginosa (MIC to 3.1 μM). Checkerboard assay (CA) and time-kill studies (TKS) experiments analyzed with the a pharmacodynamic model, have potentials for in vitro evaluation of new and existing antimicrobials. In this study, CA and TKS were used to identify the potential benefits of an antibiotic combination (i.e., synthetic compounds, vancomycin, and rifampicin) for the treatment of MRSA and M. tuberculosis infections. CA experiments indicated that the association of compounds 1a and 2a with vancomycin and compound 3 with rifampicin combination have a synergistic effect against a MRSA and M. tuberculosis infections, respectively. Furthermore, the analysis of TKS uncovered bactericidal and time-dependent properties of the synthetic compounds that may be due to variations in hydrophobicity and mechanisms of action of the molecules tested. The results of cross-referencing antimicrobial activity, and toxicity, CA, and Time-Kill experiments establish that these synthetic compounds are promising potential leads, with a favorable therapeutic index for antimicrobial drug development.

ELECTROWETTING FLUIDS

This invention relates to electrowetting fluids, the use of these fluids for the preparation of an electrowetting displays devices, and electrowetting display devices comprising such fluids.

PARTICLES FOR ELECTROPHORETIC DISPLAYS

This invention relates to polymer particles, a process for their preparation, the use of these particles for the preparation of an electrophoretic device, electrophoretic displays comprising such particle, and new polymerisable dyes.

PARTICLES FOR ELECTROWETTING DISPLAYS

This invention relates to polymer particles for use in electrowetting fluids and electrowetting displays devices comprising such particles.

ELECTROPHORETIC FLUID

This invention relates to electrophoretic fluid comprising solvents, a highly absorbing dye, and charged particles of different colour, and electrophoretic display devices comprising such fluids.